In previous DLBCL studies, highly variable (24–80%) BCL2 positivity rates were observed, which would be mainly due to subjective and semiquantitative interpretation and the absence of the established cutoff value for BCL2 expression by immunohistochemistry (IHC). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.